OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Tsao on the Investigation of Cabozantinib With Nivolumab and Ipilimumab in RCC

May 16th 2023

Che-Kai Tsao, MD, discusses the investigation of cabozantinib in combination with nivolumab and ipilimumab in patients with renal cell carcinoma.

Dr Goff on the Investigation of Adjuvant Atezolizumab Plus Bevacizumab in HCC

May 16th 2023

Laura Goff, MD, discusses the investigation of adjuvant atezolizumab plus bevacizumab in hepatocellular carcinoma.

Dr Henick on the Use of Neoadjuvant Atezolizumab Plus Chemotherapy in NSCLC

May 16th 2023

Brian Henick, MD, discusses the 3-year updated data from a phase 2 trial investigating treatment with neoadjuvant atezolizumab plus chemotherapy in patients with resectable non–small cell lung cancer.

Dr Habermann on Ongoing Trials in MCL and MZL

May 16th 2023

Thomas M. Habermann, MD, discusses ongoing clinical trials in mantle cell lymphoma and marginal zone lymphoma.

Dr Mascarenhas on First-line Treatment Decisions in Myelofibrosis

May 16th 2023

John Mascarenhas, MD, discusses first-line treatment decisions for patients with myelofibrosis.

​​Dr Byndloss on the Relationship Between Gut Health and the Risk of Developing CRC

May 16th 2023

Mariana X. Byndloss, DVM, PhD, discusses the relationship between the gut microbiome and the risk of developing cancers such as colorectal cancer.

Dr Naumann on the Changing Treatment Landscape in Cervical Cancer

May 16th 2023

R. Wendel Naumann, MD, FACOG, FACS, discusses how the evolution of immunotherapy has changed the treatment landscape for patients with recurrent or metastatic cervical cancer.

Dr Habermann on Data Leading to the Withdrawal of Ibrutinib in MCL

May 16th 2023

Thomas M. Habermann, MD, discusses the data that led to the decision to withdraw the indication for ibrutinib for the treatment of patients with mantle cell lymphoma.

Dr Khalil on the Future Investigations of Immunotherapy in NSCLC

May 15th 2023

Maya Khalil, MD, discusses the future investigations of immunotherapy in non–small cell lung cancer.

Dr Bal on Unmet Needs With CAR T-cell Therapy in Multiple Myeloma

May 15th 2023

Susan Bal, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Dr Gibson on Advancements in Biomarker Identification in Gastric/GEJ Adenocarcinoma

May 15th 2023

Michael K. Gibson MD, PhD, discusses advancements in the identification of key biomarkers for patients with gastric or gastroesophageal junction adenocarcinoma, and the subsequent development of biomarker-driven therapeutics in this disease space.

Dr Galsky on the Importance of Improved Disease Classification Within Non–Clear Cell RCC

May 15th 2023

Matthew Galsky, MD, discusses the importance of developing specific disease classifications within non–clear cell renal cell carcinomas.

Dr Reuss on the Investigation of LP-300 in Lung Adenocarcinoma

May 15th 2023

Joshua Reuss, MD, discusses the background of LP-300 and the rationale for evaluating the agent in the phase 2 HARMONIC trial in a never-smoker population of patients with advanced lung adenocarcinoma.

Dr Habermann on the Withdrawal of U.S. Indications for Ibrutinib in MCL and MZL

May 12th 2023

Thomas M. Habermann, MD, discusses the withdrawal of United States indications for ibrutinib in patients with mantle cell lymphoma who have previously received at least 1 therapy and in those with marginal zone lymphoma who require systemic treatment and have received at least 1 prior anti–CD20-based therapy.

Dr Ryan on the Role of Adjuvant Therapy in RCC

May 12th 2023

Christopher W. Ryan, MD, discusses the role of adjuvant therapy for patients with renal cell carcinoma.

Dr Goff on Key Takeaways from the SWOG 1815 Trial in Biliary Tract Cancers

May 12th 2023

Laura Goff, MD, discusses the key takeaways from results of the phase 3 SWOG 1815 trial in newly diagnosed patients with advanced biliary tract cancers.

Dr Zonder on the Management of Bispecific Antibody–Associated Toxicities in Multiple Myeloma

May 12th 2023

Jeffery Zonder, MD, discusses the management of toxicities associated with bispecific antibodies in patients with multiple myeloma.

Dr Khalil on Benefits Derived From the POSEIDON Regimen in Metastatic NSCLC

May 12th 2023

Maya Khalil, MD, discusses the use of first-line durvalumab plus tremelimumab in patients with non–small cell lung cancer enrolled in the phase 3 POSEIDON trial, and sheds light on histologies and mutations that are associated with increased benefit with this regimen.

Dr Gibson on Current and Emerging Biomarkers in Gastric/GEJ Adenocarcinoma

May 11th 2023

Michael K. Gibson MD, PhD, discusses current and emerging biomarkers in the treatment of patients with gastric or gastroesophageal junction adenocarcinoma.

Dr Mascarenhas on the Background of the MANIFEST-2 Trial in Myelofibrosis

May 11th 2023

John Mascarenhas, MD, discusses the background of the phase 3 MANIFEST-2 trial investigating the combination of pelabresib and ruxolitinib vs ruxolitinib plus placebo in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.

NEXT PAGE
PREVIOUS PAGE